Simultaneous up-regulation of Kindlin-2 and silencing of YB-1 or β-catenin in glioma cells resulted in a decrease in EGFR mRNA levels and transcriptional activity, and disruption of the Kindlin-2 binding sites in the EGFR promoter. This evidence concerns the gene EGFR and central nervous system cancer.